




Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN

Last Trade:	3.05
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.01  (+0.329%)
Day Range	3.03 - 3.10
52-Week Range	2.56 - 4.47
Volume	1,147,448

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 14, 2017

[Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee](#)

Aug 2, 2017

[Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations](#)

Jul 26, 2017

[Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017](#)

Jun 12, 2017

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides](#)

Jun 1, 2017

[Amarin to Present at the Jefferies 2017 Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)